Annual CFI
-$674.00 K
-$60.57 M-101.13%
31 December 2023
Summary:
Apellis Pharmaceuticals annual cash flow from investing activities is currently -$674.00 thousand, with the most recent change of -$60.57 million (-101.13%) on 31 December 2023. During the last 3 years, it has risen by +$316.31 million (+99.79%). APLS annual CFI is now -100.27% below its all-time high of $247.62 million, reached on 31 December 2021.APLS Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
$0.00
+$90.00 K+100.00%
30 September 2024
Summary:
Apellis Pharmaceuticals quarterly cash flow from investing activities is currently $0.00, with the most recent change of +$90.00 thousand (+100.00%) on 30 September 2024. Over the past year, it has increased by +$47.00 thousand (+100.00%). APLS quarterly CFI is now -100.00% below its all-time high of $198.76 million, reached on 30 September 2020.APLS Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
-$379.00 K
+$47.00 K+11.03%
30 September 2024
Summary:
Apellis Pharmaceuticals TTM cash flow from investing activities is currently -$379.00 thousand, with the most recent change of +$47.00 thousand (+11.03%) on 30 September 2024. Over the past year, it has dropped by -$123.83 million (-100.31%). APLS TTM CFI is now -100.11% below its all-time high of $331.58 million, reached on 31 March 2023.APLS TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
APLS Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -101.1% | +100.0% | -100.3% |
| 3 y3 years | +99.8% | -100.0% | -100.2% |
| 5 y5 years | -100.0% | +100.0% | +75.4% |
APLS Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -100.3% | +99.8% | -100.0% | +100.0% | -100.1% | +46.5% |
| 5 y | 5 years | -100.3% | +99.8% | -100.0% | +100.0% | -100.1% | +99.9% |
| alltime | all time | -100.3% | +99.8% | -100.0% | +100.0% | -100.1% | +99.9% |
Apellis Pharmaceuticals Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $0.00(-100.0%) | -$379.00 K(-11.0%) |
| June 2024 | - | -$90.00 K(-69.3%) | -$426.00 K(-39.8%) |
| Mar 2024 | - | -$293.00 K(-7425.0%) | -$708.00 K(+5.0%) |
| Dec 2023 | -$674.00 K(-101.1%) | $4000.00(-108.5%) | -$674.00 K(-100.5%) |
| Sept 2023 | - | -$47.00 K(-87.4%) | $123.45 M(-50.3%) |
| June 2023 | - | -$372.00 K(+43.6%) | $248.28 M(-25.1%) |
| Mar 2023 | - | -$259.00 K(-100.2%) | $331.58 M(+453.6%) |
| Dec 2022 | $59.89 M(-75.8%) | $124.13 M(-0.5%) | $59.89 M(+188.7%) |
| Sept 2022 | - | $124.78 M(+50.5%) | $20.74 M(-72.6%) |
| June 2022 | - | $82.93 M(-130.5%) | $75.61 M(-38.2%) |
| Mar 2022 | - | -$271.95 M(-420.0%) | $122.43 M(-50.6%) |
| Dec 2021 | $247.62 M(-178.1%) | $84.98 M(-52.7%) | $247.62 M(+52.3%) |
| Sept 2021 | - | $179.65 M(+38.5%) | $162.54 M(-10.5%) |
| June 2021 | - | $129.75 M(-188.4%) | $181.66 M(-177.0%) |
| Mar 2021 | - | -$146.76 M(>+9900.0%) | -$235.90 M(-25.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2020 | -$316.99 M(>+9900.0%) | -$91.00 K(-100.0%) | -$316.99 M(-0.0%) |
| Sept 2020 | - | $198.76 M(-169.1%) | -$317.05 M(-38.6%) |
| June 2020 | - | -$287.81 M(+26.3%) | -$516.29 M(+125.8%) |
| Mar 2020 | - | -$227.85 M(>+9900.0%) | -$228.67 M(>+9900.0%) |
| Dec 2019 | -$1.69 M(<-9900.0%) | -$155.00 K(-67.1%) | -$1.69 M(+10.1%) |
| Sept 2019 | - | -$471.00 K(+145.3%) | -$1.54 M(+44.1%) |
| June 2019 | - | -$192.00 K(-78.1%) | -$1.07 M(+21.9%) |
| Mar 2019 | - | -$875.00 K(<-9900.0%) | -$875.00 K(<-9900.0%) |
| Dec 2018 | $0.00(0.0%) | $0.00(0.0%) | $0.00(0.0%) |
| Sept 2018 | - | $0.00(0.0%) | $0.00(0.0%) |
| June 2018 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2018 | - | $0.00 | $0.00 |
| Dec 2017 | $0.00(-100.0%) | - | - |
| Dec 2014 | -$19.90 K(<-9900.0%) | - | - |
| Dec 2013 | $0.00 | - | - |
FAQ
- What is Apellis Pharmaceuticals annual cash flow from investing activities?
- What is the all time high annual CFI for Apellis Pharmaceuticals?
- What is Apellis Pharmaceuticals annual CFI year-on-year change?
- What is Apellis Pharmaceuticals quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Apellis Pharmaceuticals?
- What is Apellis Pharmaceuticals quarterly CFI year-on-year change?
- What is Apellis Pharmaceuticals TTM cash flow from investing activities?
- What is the all time high TTM CFI for Apellis Pharmaceuticals?
- What is Apellis Pharmaceuticals TTM CFI year-on-year change?
What is Apellis Pharmaceuticals annual cash flow from investing activities?
The current annual CFI of APLS is -$674.00 K
What is the all time high annual CFI for Apellis Pharmaceuticals?
Apellis Pharmaceuticals all-time high annual cash flow from investing activities is $247.62 M
What is Apellis Pharmaceuticals annual CFI year-on-year change?
Over the past year, APLS annual cash flow from investing activities has changed by -$60.57 M (-101.13%)
What is Apellis Pharmaceuticals quarterly cash flow from investing activities?
The current quarterly CFI of APLS is $0.00
What is the all time high quarterly CFI for Apellis Pharmaceuticals?
Apellis Pharmaceuticals all-time high quarterly cash flow from investing activities is $198.76 M
What is Apellis Pharmaceuticals quarterly CFI year-on-year change?
Over the past year, APLS quarterly cash flow from investing activities has changed by +$47.00 K (+100.00%)
What is Apellis Pharmaceuticals TTM cash flow from investing activities?
The current TTM CFI of APLS is -$379.00 K
What is the all time high TTM CFI for Apellis Pharmaceuticals?
Apellis Pharmaceuticals all-time high TTM cash flow from investing activities is $331.58 M
What is Apellis Pharmaceuticals TTM CFI year-on-year change?
Over the past year, APLS TTM cash flow from investing activities has changed by -$123.83 M (-100.31%)